A topical cream containing glucosamine and chondroitin sulphate reduced joint pain in osteoarthritis of the knee


QUESTION: In patients with osteoarthritis of the knee, is a topical cream containing glucosamine sulphate, chondroitin sulphate, and camphor more effective than placebo for relieving joint pain?

Design
Randomised (allocation concealed*), blinded (patients, healthcare providers, and data collectors)*, controlled trial with 8 weeks of follow up.

Setting
An outpatient clinic at Monash Medical Center, Australia.

Patients
63 patients with objectively documented osteoarthritis of the knee who had had knee pain rated >4 cm on a 10 cm visual analogue scale in one or both knees for >4 weeks. Exclusion criteria included women of childbearing age who were not using contraception or were pregnant, and patients who had a regular requirement for analgesia for conditions unrelated to osteoarthritis or had used oral or topical glucosamine in the previous 6 weeks. Follow up was 94% (mean age 63 y, 54% women).

Intervention
Patients were allocated to a topical glucosamine/chondroitin preparation (n=32) or placebo (n=31), to be used as required for 8 weeks. The glucosamine/chondroitin preparation was a water soluble cream containing glucosamine sulphate [3.0 mg/g†], chondroitin sulphate [7.2 mg/g†], and shark cartilage [14 mg/g†], of which 10–30% is chondroitin sulphate, camphor [32 mg/g], and scented with peppermint oil (9 mg/g). The placebo preparation was a simple cosmetic cream containing conventional skin emollients, petrolatum and mineral oil, conventional emulsifiers, stearic acid and glycerol stearate, and a lesser amount of peppermint oil.

Main outcome measures
The main outcome was pain rating by patients based on a 10 cm visual analogue scale that was assessed in the clinic at 0, 4, and 8 weeks. Secondary outcomes included joint pain, stiffness, and a measure of physical function using the Western Ontario and McMaster Universities Osteoarthritis Index and quality of life measured by the Short Form-36 questionnaire.

Main results
Analysis was by intention to treat. At 4 and 8 weeks, reduction in pain was greater in the glucosamine/chondroitin preparation group than in the placebo group (table). The groups did not differ for any other outcomes.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Follow up</th>
<th>Active cream</th>
<th>Placebo</th>
<th>Difference between groups (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean change from baseline in joint pain (visual analogue scale 0–10 cm)</td>
<td>Week 4</td>
<td>-2.6</td>
<td>-1.4</td>
<td>1.2 (0.1 to 2.4)</td>
</tr>
<tr>
<td></td>
<td>Week 8</td>
<td>-3.3</td>
<td>-1.6</td>
<td>1.8 (0.6 to 2.9)</td>
</tr>
</tbody>
</table>

1†CI defined in glossary.

Conclusion
In patients with osteoarthritis of the knee, a topical cream containing glucosamine sulphate, chondroitin sulphate, and camphor was more effective than placebo for relieving joint pain.

*See glossary.
†Information provided by author.

COMMENTARY
The double blind, placebo controlled trial by Cohen et al is one of the first studies performed with adequate methodology to show that topical application of glucosamine and chondroitin sulphate is effective at relieving symptoms from osteoarthritis of the knee. Both chondroitin sulphate and glucosamine sulphate are major components of the extracellular matrix of many connective tissues including cartilage. They act as a preferred substrate for the biosynthesis of glycosaminoglycan chains and, subsequently, for the production of aggrecan and other proteoglycans in cartilage.

Two previous independent studies*† have shown that glucosamine sulphate was able to act both on symptoms and structure modifications observed in osteoarthritic knee joints. The current study is the first, however, to use a double blind, placebo controlled study design for the evaluation of a topical cream containing glucosamine sulphate, chondroitin sulphate, and camphor. The 8 week trial period included the 4 weeks needed to observe the onset of action of the topical cream. The statistical significance observed for the difference in pain reduction between the glucosamine/chondroitin preparation and placebo groups (visual analogue scale measurements) after 4 weeks remained significant after 8 weeks. Unfortunately, the effects observed on measures of physical function (Western Ontario and McMaster Universities Osteoarthritis Index) and quality of life (Short Form-36 questionnaire) were less striking than the one assessed by the visual analogue scale pain score.

Although this study is of relatively limited size (63 patients), it shows that topical preparations can be of substantial benefit in the management of symptoms of osteoarthritis of the knee. Because the difference observed between the glucosamine/chondroitin preparation and placebo groups was clinically relevant, these preparations can be particularly helpful in patients who cannot tolerate analgesics or non-steroidal anti-inflammatory drugs to manage their symptoms. This study adds to the body of evidence that topical chondroitin sulphate and glucosamine sulphate should be positively considered for the symptomatic management of osteoarthritis.

Jean-Yves Reginster, MD, PhD
University of Liege, Liege, Belgium